Semaglutide: Mechanism of Action

Mechanism of Action

Semaglutide selectively activates the GLP-1 receptor (GLP-1R), a Class B1 G protein-coupled receptor expressed on pancreatic beta cells, hypothalamic neurons, cardiomyocytes, and GI smooth muscle.[1] Receptor activation initiates Gαs-mediated signaling, increasing intracellular cyclic AMP (cAMP) and engaging downstream Protein Kinase A (PKA) and Epac2 (RAPGEF4) effector pathways. In pancreatic β-cells, this cascade closes ATP-sensitive potassium channels, depolarizes the cell membrane, opens voltage-gated calcium channels, and triggers glucose-dependent insulin granule exocytosis — a glucose-conditional mechanism that intrinsically limits hypoglycemia risk relative to sulfonylurea-class compounds.[1]

In addition to direct β-cell signaling, semaglutide engages central GLP-1 receptors expressed on POMC/CART neurons in the arcuate nucleus of the hypothalamus and on neurons in the area postrema and nucleus tractus solitarius. Activation of these neuronal populations suppresses appetite, modulates reward-related food intake, and contributes to the substantial weight loss observed in the STEP and SELECT trial programs.[4][5] The molecule's high plasma protein binding (>99%, predominantly to albumin) and slow renal/hepatic clearance produce stable steady-state concentrations after approximately 4–5 weekly doses, supporting consistent receptor occupancy throughout the dosing interval.[2]

Key Downstream Effects

Target Tissue	Mechanism	Clinical Effect
Pancreatic Beta Cells	cAMP/PKA activation → glucose-dependent insulin secretion	Improved glycemic control; low hypoglycemia risk
Pancreatic Alpha Cells	Suppresses glucagon secretion (glucose-dependent)	Reduced hepatic glucose output
Hypothalamus	Activates POMC/CART neurons; inhibits NPY/AgRP	Appetite suppression; reduced caloric intake
GI Tract	Delays gastric emptying via vagal afferents	Increased satiety; reduced postprandial glucose
Cardiovascular	Anti-inflammatory, anti-atherosclerotic, endothelial protection	Investigated in cardiovascular research models (SELECT trial)

The C18 fatty diacid acylation enables reversible albumin binding, creating a circulating depot that extends the half-life from ~2 minutes (native GLP-1) to ~168 hours, enabling once-weekly dosing.[2][8]

Beta-Arrestin Recruitment and Biased Agonism Research

Mechanistic research into the GLP-1R has demonstrated that semaglutide displays a partial bias toward Galpha-s-mediated cAMP signaling relative to beta-arrestin recruitment. This signaling profile is investigated as a determinant of receptor desensitization kinetics and downstream insulinotropic durability in pancreatic beta-cell models, providing a comparative tool for understanding biased agonism across the broader incretin-receptor family.[1]

Hypothalamic Neuronal Compartmentalization

Functional MRI and electrophysiological investigations in animal models have identified distinct neuronal populations engaged by semaglutide in the arcuate nucleus, area postrema, and nucleus tractus solitarius, with cross-talk to mesolimbic reward pathways. This neuro-anatomical compartmentalization is a research framework for distinguishing satiety-driven from reward-driven reductions in caloric intake.[4]